Skip to main content

Table 3 Changes in the number of pigs developing porcine circovirus type 2 (PCV2) and wild-type classical swine fever virus (CSFV) viremia in various treatment groups over time after CSFV challengea.

From: Porcine circovirus type 2 (PCV2) infection decreases the efficacy of an attenuated classical swine fever virus (CSFV) vaccine

dpi 27 30 33 36 39 42 45
Group 1 6/0/6b 6/3/6 6/2/6 6/1/6 6/1/6 6/1/6 6/0/6
Group 2 6/0/6 6/6/6 6/6/6 6/6/6 4/4/4 1/1/1 0/0/0
Group 3 0/0/3 0/0/3 0/0/3 0/0/3 0/0/3 0/0/3 0/0/3
Group 4 0/0/3 0/3/3 0/3/3 0/3/3 0/3/3 0/3/3 0/0/0
  1. Group 1: PCV2-infected/LPC-vaccinated/CSFV-challenged; group 2: PCV2-infected/CSFV-challenged; group 3: LPC-vaccinated/CSFV-challenged, and group 4: CSFV-challenged.
  2. aThe pigs were inoculated with 105.3 TCID50 of PCV2 (group 1 and 2), 1 dose of LPC vaccine (group 1 and 3), and 106.8 TCID50 of wild-type CSFV (ALD) (group 1, 2, 3, and 4) at 0, 12, and 27 dpi, respectively. The PCV2 and wild-type CSFV loads in plasma were detected by real-time PCR or reverse transcription real-time PCR, respectively.
  3. bNumber of PCV2-positive animals/number of wild-type CSFV-positive animals/number of surviving animals.